브랜드 제네릭 시장 : 제품 유형, 약제 유형, 투여 경로, 적응증, 유통 채널별 - 세계 예측(2025-2030년)

The Branded Generics Market was valued at USD 432.30 billion in 2023, expected to reach USD 494.29 billion in 2024, and is projected to grow at a CAGR of 14.66%, to USD 1,126.43 billion by 2030.

Branded generics refer to off-patent drugs that are sold under a brand name by pharmaceutical companies, offering a cost-effective alternative to generic drugs while retaining brand loyalty advantages. Their necessity arises from the balance they offer between affordability and quality assurance, making them integral in regions where healthcare costs are critical. These drugs are typically applied across multiple therapeutic areas, used in treatments from chronic diseases to acute care, with end-users ranging from healthcare providers, hospitals, and individual consumers. Key factors driving the growth of branded generics include an increase in the prevalence of chronic diseases, rising demand for affordable medication, and expansion in emerging markets where healthcare access is limited yet increasingly crucial. Latest opportunities lie in leveraging digital marketing channels to enhance brand presence and focusing on strategic partnerships or acquisitions in emerging markets to widen distribution networks. However, the market faces challenges such as stringent regulatory environments, fierce price competition, and intellectual property concerns, which can hinder growth. Limitations also stem from the constant evolution of healthcare policies that can affect market access and drug pricing. Innovations could explore the development of biosimilars and personalized medicine as brands could differentiate by focusing on patient-specific solutions. Additionally, investing in advanced drug delivery mechanisms and digital health monitoring tools could provide brands a competitive edge. The nature of the branded generics market is moderately competitive, with numerous global and regional players striving for market share, necessitating continual innovation and customer-oriented strategies. For sustained growth, companies are recommended to invest in R&D, optimize supply chain efficiency, and prioritize emerging market entry strategies while adapting to regulatory changes proactively. The need for both operational agility and strong brand differentiation is paramount in capturing market opportunities while navigating the limitations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Branded Generics Market

The Branded Generics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of chronic diseases necessitating the use of generic medications
  • Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
• Market Restraints
  • Concerns associated with quality variations in branded generic medications
• Market Opportunities
  • Novel bioequivalence studies and efforts by market players to expand branded generics business
• Market Challenges
  • Litigation issues and issues related to price erosion of innovator drugs

Porter's Five Forces: A Strategic Tool for Navigating the Branded Generics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Branded Generics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Branded Generics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Branded Generics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Branded Generics Market

A detailed market share analysis in the Branded Generics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Branded Generics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Branded Generics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddy's Laboratories Ltd., Lupin Limited, Viatris Inc., Sandoz International GmbH by Novartis AG, Bausch Health Companies Inc., GlaxoSmithKline PLC, Amneal Pharmaceuticals LLC, Eris Lifesciences Limited, Alkem Laboratories Ltd., Cipla Limited, Zentiva Group, a.s., Nichi-Iko Pharmaceutical Co., Ltd., Endo International PLC, Aurobindo Pharma Limited, AstraZeneca PLC, Eva Pharma, Hetero Drugs Limited, Abbott Laboratories, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Pfizer Inc., Aspen Pharmacare Holdings Limited, Sun Pharmaceutical Industries Ltd., Ajanta Pharma Ltd., Apotex Inc., Bristol-Myers Squibb Company, Sanofi S.A., Micro Labs Limited, Torrent Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Trade Named Generics and Value-Added.
• Based on Drug Type, market is studied across Alkylating Agents, Anti-depressants, Anti-epileptics, Anti-hypertensive, Anti-psychotics, Antimetabolites, Hormones, and Lipid Lowering Drugs.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
• Based on Indication, market is studied across Acute & Chronic Pain, Cardiovascular Diseases, Dermatological Diseases, Gastrointestinal Diseases, Neurological Diseases, and Oncology.
• Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacy and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
    • 5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with quality variations in branded generic medications
  • 5.1.3. Opportunities
    • 5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
  • 5.1.4. Challenges
    • 5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
  • 5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
  • 5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
  • 5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
  • 5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Branded Generics Market, by Product

• 6.1. Introduction
• 6.2. Trade Named Generics
• 6.3. Value-Added

7. Branded Generics Market, by Drug Type

• 7.1. Introduction
• 7.2. Alkylating Agents
• 7.3. Anti-depressants
• 7.4. Anti-epileptics
• 7.5. Anti-hypertensive
• 7.6. Anti-psychotics
• 7.7. Antimetabolites
• 7.8. Hormones
• 7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Topical

9. Branded Generics Market, by Indication

• 9.1. Introduction
• 9.2. Acute & Chronic Pain
• 9.3. Cardiovascular Diseases
• 9.4. Dermatological Diseases
• 9.5. Gastrointestinal Diseases
• 9.6. Neurological Diseases
• 9.7. Oncology

10. Branded Generics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Offline
  • 10.2.1. Hospital Pharmacy
  • 10.2.2. Retail Pharmacy
• 10.3. Online

11. Americas Branded Generics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Branded Generics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Vyvanse Generics Approved by FDA
  • 14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
  • 14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
  • 14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
  • 14.3.5. Dr Reddy's Enters Trade Generics Business In Domestic Market
  • 14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
  • 14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
  • 14.3.8. Cipla Launches 'Easylax L',A Sugar-Free Oral Emulsion Laxative For Constipation Relief
  • 14.3.9. Procaps Group to Acquire Grupo Somar from Advent International

Companies Mentioned

• 1. Dr. Reddy's Laboratories Ltd.
• 2. Lupin Limited
• 3. Viatris Inc.
• 4. Sandoz International GmbH by Novartis AG
• 5. Bausch Health Companies Inc.
• 6. GlaxoSmithKline PLC
• 7. Amneal Pharmaceuticals LLC
• 8. Eris Lifesciences Limited
• 9. Alkem Laboratories Ltd.
• 10. Cipla Limited
• 11. Zentiva Group, a.s.
• 12. Nichi-Iko Pharmaceutical Co., Ltd.
• 13. Endo International PLC
• 14. Aurobindo Pharma Limited
• 15. AstraZeneca PLC
• 16. Eva Pharma
• 17. Hetero Drugs Limited
• 18. Abbott Laboratories
• 19. Glenmark Pharmaceuticals Limited
• 20. Fresenius Kabi AG
• 21. Pfizer Inc.
• 22. Aspen Pharmacare Holdings Limited
• 23. Sun Pharmaceutical Industries Ltd.
• 24. Ajanta Pharma Ltd.
• 25. Apotex Inc.
• 26. Bristol-Myers Squibb Company
• 27. Sanofi S.A.
• 28. Micro Labs Limited
• 29. Torrent Pharmaceuticals Ltd.
• 30. Teva Pharmaceutical Industries Ltd.